"Similarly high survival rates were seen whether using product made for the Phase 3 clinical trial MSBGVHD001 between 2015-2018 or made with the validated manufacturing process proposed for commercial release and used under Emergency Investigational New Drug (EIND) protocol through 2023.
Mesoblast believes that the totality of these clinical studies, together with additional potency assay datacurrently being generated using the IL-2R alpha inhibition potency assay in place during the pediatricPhase 3 trial, will both support approval for the pediatric indication and provide a link between theRYONCIL product that was used in the pediatric Phase 3 trial and available commercial inventory.
[...]
In contrast, 100-day survival was 63% after remestemcel-L treatment was used under expanded access in 71 patients aged 12 and older with SR-aGVHD who failed to respond to at least one additional agent, such as ruxolitinib."
https://www.mesoblast.com/images/Mesoblast_-_Corporate_Deck_-_NOV_2023_FINAL.pdf
It started off with a trial of 54 patients, next step was selecting the data from 25 patients and artificially create a control group based, which brought it back to (25+27=) 52 patients. Problem there was, that these 25 patients could have received lots from more than one donor which could be a confounding factor as even one ODAC presented slide showed differences in INFgamma levels between three different donors. And SI has been questioned on this slide during ODAC but shifted the focus to TNFalpha straight away.
- Forums
- ASX - By Stock
- Ann: Investor Presentation
"Similarly high survival rates were seen whether using product...
-
-
- There are more pages in this discussion • 44 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CYP (ASX) to my watchlist
(20min delay)
|
|||||
Last
20.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $37.01M |
Open | High | Low | Value | Volume |
20.5¢ | 20.5¢ | 20.5¢ | $454 | 2.214K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 12223 | 20.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
22.5¢ | 5176 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 12223 | 0.205 |
2 | 105000 | 0.200 |
2 | 68825 | 0.195 |
3 | 122713 | 0.190 |
3 | 65055 | 0.180 |
Price($) | Vol. | No. |
---|---|---|
0.225 | 5176 | 1 |
0.230 | 7000 | 1 |
0.250 | 2225 | 1 |
0.255 | 187726 | 1 |
0.270 | 30000 | 1 |
Last trade - 11.06am 14/08/2024 (20 minute delay) ? |
Featured News
CYP (ASX) Chart |